Literature DB >> 28176303

Association between age and access to immediate breast reconstruction in women undergoing mastectomy for breast cancer.

R Jeevan1,2, J P Browne3,4, C Gulliver-Clarke5, J Pereira6,7, C M Caddy8, J H P van der Meulen1,3, D A Cromwell1,3.   

Abstract

BACKGROUND: National guidelines state that patients with breast cancer undergoing mastectomy in England should be offered immediate breast reconstruction (IR), unless precluded by their fitness for surgery or the need for adjuvant therapies.
METHODS: A national study investigated factors that influenced clinicians' decision to offer IR, and collected data on case mix, operative procedures and reconstructive decision-making among women with breast cancer having a mastectomy with or without IR in the English National Health Service between 1 January 2008 and 31 March 2009. Multivariable logistic regression was used to examine the relationship between whether or not women were offered IR and their characteristics (tumour burden, functional status, planned radiotherapy, planned chemotherapy, perioperative fitness, obesity, smoking status and age).
RESULTS: Of 13 225 women, 6458 (48·8 per cent) were offered IR. Among factors the guidelines highlighted as relevant to decision-making, the three most strongly associated with the likelihood of an offer were tumour burden, planned radiotherapy and performance status. Depending on the combination of their values, the probability of an IR offer ranged from 7·4 to 85·1 per cent. A regression model that included all available factors discriminated well between whether or not women were offered IR (c-statistic 0·773), but revealed that increasing age was associated with a fall in the probability of an IR offer beyond that expected from older patients' tumour and co-morbidity characteristics.
CONCLUSION: Clinicians are broadly following guidance on the offer of IR, except with respect to patients' age.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28176303     DOI: 10.1002/bjs.10453

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Achieving consistent and equitable access to post mastectomy breast reconstruction.

Authors:  Anne C O'Neill
Journal:  Gland Surg       Date:  2020-08

2.  Reconstructive utilisation and outcomes following mastectomy surgery in women with breast cancer treated in England.

Authors:  R Jeevan
Journal:  Ann R Coll Surg Engl       Date:  2019-08-16       Impact factor: 1.891

Review 3.  Surgery in the Older Patient with Breast Cancer.

Authors:  Julia Frebault; Carmen Bergom; Amanda L Kong
Journal:  Curr Oncol Rep       Date:  2019-06-25       Impact factor: 5.075

4.  Patient-Reported Satisfaction after Prophylactic Operations of the Breast.

Authors:  Katja Keller; Cornelia Meisel; Nannette Grübling; Andrea Petzold; Pauline Wimberger; Karin Kast
Journal:  Breast Care (Basel)       Date:  2019-02-15       Impact factor: 2.860

5.  Surgeons’ Recommendation is the Factor in Determining the Breast Cancer Surgery Procedures: an Experience from Ruralzzm321990Hospital in Thailand

Authors:  Ajaree Sattaratnamai; Noppawat Samankatiwat; Visnu Lohsiriwat
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

6.  Association of sociodemographic and oncological features with decision on implant-based versus autologous immediate postmastectomy breast reconstruction in Chinese patients.

Authors:  Zhuming Yin; Yan Wang; Jingyan Sun; Qingfeng Huang; Jing Liu; Shanshan He; Chunyong Han; Shu Wang; Bowen Ding; Jian Yin
Journal:  Cancer Med       Date:  2019-04-05       Impact factor: 4.452

7.  Regional variation in immediate breast reconstruction in Australia.

Authors:  K L Flitcroft; M E Brennan; D S J Costa; A J Spillane
Journal:  BJS Open       Date:  2017-10-26

8.  Higher Distress in Patients with Breast Cancer Is Associated with Declining Breast Reconstruction.

Authors:  Joseph P Corkum; Kate Butler; Toni Zhong
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-02-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.